Morepen Laboratories Limited

BSE: 500288 NSE: MOREPENLAB
Morepen Laboratories Limited - pharma in Himachal Pradesh, India. FY 2026 financials & compliance.
CIN L24231HP1984PLC006028 Incorporated 01 December 1984 ROC Himachal Pradesh HQ Himachal Pradesh, India
Active Listed - NSE: MOREPENLAB · BSE: 500288 Public Limited Company pharma
Data last updated
Market Cap
₹6,324 Cr
MOREPENLAB · NSE
Share Price
₹117.67
+1.95% today
Revenue
₹1,806 Cr
FY 2025-26 · -0.3% YoY
EBITDA
₹126 Cr
Margin 7.0%
Net Profit
₹63.79 Cr
FY 2025-26 · -46.0% YoY
P/E (TTM)
56.7x
P/B 5.3x
ROE
5.4%
ROCE 7.9%
Debt / Equity
0.13
Interest cover 18.4x

About Morepen Laboratories Limited

Data last updated:

Morepen Laboratories Limited is a public limited company based in Himachal Pradesh, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 01 December 1984 and has been in existence for over 42 years.

The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN L24231HP1984PLC006028. Its GSTIN is 02AABCM1083B1ZA (Himachal Pradesh). The company holds 23 GST registrations, of which 13 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500288 and NSE: MOREPENLAB.

The company has an authorised share capital of ₹250 Cr and a paid-up capital of ₹109.58 Cr. It was formerly known as Morepen Laboratories Private Limited. It is led by directors including Sushil Suri (Managing Director) and Sanjay Suri (Whole-Time Director).

Its last annual general meeting (AGM) was held on 06 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Village Morepen Nalagarh Road Near Baddi Distt Solan, Himachal Pradesh, India – 173205.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,805.69 Cr, a decline of 0.3% compared to the previous year. For the same year it recorded a net profit of ₹63.79 Cr (net margin 3.5%) and EBITDA of ₹125.62 Cr (EBITDA margin 7%). The net worth stands at ₹1,246.43 Cr (up 7.8% YoY). Total assets are valued at ₹1,499.35 Cr (up 12.2% YoY).

The company has about 557 employees on its provident fund (EPFO) records. Its group structure includes 6 subsidiaries.

The company is associated with 1 brand: Morepen Laboratories. As per MCA filings, the company has open charges of ₹61.36 Cr and satisfied charges of ₹2,644.6 Cr on record. Court records list 637 cases involving the company, including 403 filed by the company and 234 filed against it; 55 cases are pending. The company has 66 deals on record (62 market trades, 3 funding rounds, 1 qip), with disclosed funding of ₹907.84 Cr; the latest was in August 2026. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Pfizer Healthcare India Private Limited with revenue of ₹1,981.45 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website morepen.com.

Company details

CIN L24231HP1984PLC006028
Registration Number 006028
Incorporation Date 01 December 1984
ROC Himachal Pradesh
Listing Status Listed - Listed on NSE (MOREPENLAB); Listed on BSE (500288)
Company Status Active
Date of Last AGM 06 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Sushil Suri Managing Director Sanjay Suri Whole-Time Director Savita Director

Contact details

Morepen Laboratories Limited's registered office is in Himachal Pradesh. Its website is morepen.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    morepen.com
  • Social Media
  • Registered Address
    Village Morepen Nalagarh Road Near Baddi Distt Solan, Himachal Pradesh, India – 173205
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Morepen Laboratories Limited, buy the company report.

Comprehensive company report
Morepen Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Morepen Laboratories operates one associated brand: Morepen Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Morepen Laboratories
API, formulations, diagnostics, and FMHG products are manufactured and marketed.morepen.com

Business activity

The main business activity of Morepen Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Morepen Laboratories Limited, buy the company report.

Financials of Morepen Laboratories Limited

FY 2025-26 filings available

Morepen Laboratories Limited reported revenue of ₹1,805.69 Cr (down 0.3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,806 Cr
-0.3% YoY
EBITDA
₹126 Cr
-27.8% YoY
Profit After Tax
₹63.79 Cr
-46.0% YoY
Net Worth
₹1,246 Cr
+7.8% YoY
Total Assets
₹1,499 Cr
+12.2% YoY
Total Debt
₹208 Cr
+97.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,8061,8121,6901,4181,5471,188853
Revenue growth-0.3%+7.2%+19.3%-8.4%+30.2%+39.3%-
EBITDA12617415979.5313711968.51
EBITDA margin+7.0%+9.6%+9.4%+5.6%+8.8%+10.0%+8.0%
Profit before tax12015513555.7512798.5139.10
Net profit63.7911896.1738.6710297.0933.57
Net profit margin+3.5%+6.5%+5.7%+2.7%+6.6%+8.2%+3.9%
EPS (₹)1.732.151.880.762.132.160.75
Balance sheet
Total assets1,4991,336915811628471444
Net worth1,2461,156847753579425284
Total debt20810529.0025.1618.5717.05133
Cash & bank68.8349.3652.1256.3145.9767.8938.88
Net working capital720647513459295139153
Cash flow
Cash from operations32.6432.0673.37(91.17)(60.24)50.8311.02
Cash from investing(126)(322)(83.30)(46.51)(31.68)(70.35)(12.46)
Cash from financing97.403005.2014466.3347.275.49
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue570485484412425466453438
Revenue growth (YoY)+34.1%+4.1%+6.9%-6.0%-6.6%---
Other income5.188.463.8130.464.414.615.344.99
EBITDA82.5424.4546.3230.7024.1742.2436.1444.07
EBITDA margin+14.5%+5.0%+9.6%+7.5%+5.7%+9.1%+8.0%+10.1%
Depreciation8.355.7510.3811.289.0316.474.931.86
Interest4.843.884.324.184.044.671.341.18
Profit before tax74.5323.2835.4345.7015.5125.7135.2146.02
Tax18.187.597.934.654.115.418.5211.17
Net profit56.3515.6927.5041.0511.4020.3026.6934.85
EPS (₹)1.030.280.500.750.200.350.490.65
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6811,5551,5381,3391,4491,112792
Revenue growth+8.2%+1.1%+14.8%-7.6%+30.3%+40.5%-
EBITDA11215316277.2712911264.47
EBITDA margin+6.7%+9.9%+10.5%+5.8%+8.9%+10.1%+8.1%
Profit before tax89.2613814963.0412694.2437.49
Net profit64.6810211146.2410194.2432.34
Net profit margin+3.9%+6.5%+7.2%+3.5%+7.0%+8.5%+4.1%
EPS (₹)1.211.852.170.902.122.100.72
Balance sheet
Total assets1,6131,314949836645488474
Net worth1,2431,182889780598445307
Total debt20595.5128.1925.1618.5717.05142
Cash & bank59.4046.3350.4855.9045.5566.9838.03
Net working capital635629515464291133160
Cash flow
Cash from operations20.4729.0877.36(102)(68.87)49.3110.86
Cash from investing(119)(280)(83.60)(36.20)(22.64)(69.09)(12.08)
Cash from financing97.122600.2814466.4147.464.65
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue541463458370391382403384
Revenue growth (YoY)+38.3%+21.2%+13.5%-3.7%+1.5%---
Other income5.318.823.935.754.093.144.874.63
Total expenses461440416342372352372341
EBITDA79.6023.3141.8927.9318.9530.1631.5743.06
EBITDA margin+14.7%+5.0%+9.2%+7.6%+4.8%+7.9%+7.8%+11.2%
Depreciation7.980.6310.0910.707.8812.254.813.79
Interest4.783.874.314.113.813.741.271.05
Profit before tax72.1527.6331.4218.8711.3517.3130.3642.85
Tax18.157.507.934.493.295.407.6910.93

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue570485484412425466453438
Revenue growth (YoY)+34.1%+4.1%+6.9%-6.0%-6.6%---
Other income5.188.463.8130.464.414.615.344.99
EBITDA82.5424.4546.3230.7024.1742.2436.1444.07
EBITDA margin+14.5%+5.0%+9.6%+7.5%+5.7%+9.1%+8.0%+10.1%
Depreciation8.355.7510.3811.289.0316.474.931.86
Interest4.843.884.324.184.044.671.341.18
Profit before tax74.5323.2835.4345.7015.5125.7135.2146.02
Tax18.187.597.934.654.115.418.5211.17
Net profit56.3515.6927.5041.0511.4020.3026.6934.85
EPS (₹)1.030.280.500.750.200.350.490.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,8061,8121,6901,4181,5471,188853
Revenue growth-0.3%+7.2%+19.3%-8.4%+30.2%+39.3%-
Other income47.1418.3613.976.1310.3112.079.48
Total expenses1,6801,6381,5321,3381,4101,070785
Employee cost233209181155164136110
EBITDA12617415979.5313711968.51
EBITDA margin+7.0%+9.6%+9.4%+5.6%+8.8%+10.0%+8.0%
Depreciation36.4328.9833.4727.9327.6430.2836.91
Interest16.418.343.711.98(7.37)1.791.98
Profit before tax12015513555.7512798.5139.10
Tax24.2837.1038.7917.0825.021.425.53
Net profit63.7911896.1738.6710297.0933.57
Net profit margin+3.5%+6.5%+5.7%+2.7%+6.6%+8.2%+3.9%
EPS (₹)1.732.151.880.762.132.160.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11011010210295.5689.9689.96
Reserves & surplus1,1371,047745651457291194
Shareholders' funds (net worth)1,2461,156847753579425284
Minority interest0.6530.730.00(0.46)(0.46)(0.46)(0.46)
Secured loans44.2453.9629.0025.1618.5717.05133
Unsecured loans16451.140.000.000.000.000.00
Total debt20810529.0025.1618.5717.05133
Total liabilities1,4991,336915811628471444
Assets
Gross block797828621656613628753
Net block513489307267252225216
Capital work in progress21.5528.3424.4517.0114.151.960.00
Investments12484.981.300.000.001.091.09
Inventories272300249229276175138
Sundry debtors333325325263251182138
Cash & bank balances68.8349.3652.1256.3145.9767.8938.88
Loans & advances46740726320816210257.14
Total current assets1,1411,082889756734527372
Total current liabilities420435376297439388219
Net working capital720647513459295139153
Total assets1,4991,336915811628471444
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash27.3816.9521.6715.8041.3913.649.60
Net cash from operating activities32.6432.0673.37(91.17)(60.24)50.8311.02
Net cash from investing activities(126)(322)(83.30)(46.51)(31.68)(70.35)(12.46)
Net cash from financing activities97.403005.2014466.3347.275.49
Net change in cash3.8110.44(4.72)5.86(25.58)27.754.04
Closing cash68.8349.3652.1256.3145.9767.8938.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-0.3%+7.2%+19.3%-8.4%+30.2%+39.3%-
EBITDA growth-27.8%+9.7%+99.5%-41.8%+15.3%+73.0%-
PBT growth-22.7%+14.6%+142.9%-56.0%+28.6%+151.9%+34.0%
Net income growth-46.0%+22.7%+148.7%-62.0%+4.7%+189.2%-
Revenue CAGR (3Y)+8.4%+5.4%+12.5%+18.4%+26.3%+25.1%+12.7%
EBITDA CAGR (3Y)+16.5%+8.4%+10.2%+5.1%+26.5%+22.3%+3.7%
Profitability & leverage
Net income margin+5.3%+6.5%+5.7%+2.7%+6.6%+8.2%+3.9%
Return on capital employed+7.9%+14.7%+16.1%+8.0%+21.7%+20.9%+8.5%
Return on net worth+5.4%+11.8%+12.1%+5.8%+20.3%+25.9%+10.2%
Debt / equity0.130.070.030.030.040.210.49
Long-term debt / equity0.070.020.000.000.000.000.01
Interest cover18.405.752.963.84-6.762.036.27
Efficiency & per share
Fixed asset turnover2.222.502.652.232.491.721.04
Inventory turnover6.326.607.085.626.867.577.33
Debtors turnover5.495.585.755.527.157.436.29
EPS (₹)1.732.151.880.762.132.160.75
Dividend per share (₹)0.200.200.000.000.000.000.00
Book value per share (₹)22.7521.1016.5814.7311.568.476.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue541463458370391382403384
Revenue growth (YoY)+38.3%+21.2%+13.5%-3.7%+1.5%---
Other income5.318.823.935.754.093.144.874.63
Total expenses461440416342372352372341
EBITDA79.6023.3141.8927.9318.9530.1631.5743.06
EBITDA margin+14.7%+5.0%+9.2%+7.6%+4.8%+7.9%+7.8%+11.2%
Depreciation7.980.6310.0910.707.8812.254.813.79
Interest4.783.874.314.113.813.741.271.05
Profit before tax72.1527.6331.4218.8711.3517.3130.3642.85
Tax18.157.507.934.493.295.407.6910.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6811,5551,5381,3391,4491,112792
Revenue growth+8.2%+1.1%+14.8%-7.6%+30.3%+40.5%-
Other income22.5915.7212.575.7610.2411.779.42
Total expenses1,5691,4011,3761,2621,3201,000728
Employee cost20617716014615012398.07
EBITDA11215316277.2712911264.47
EBITDA margin+6.7%+9.9%+10.5%+5.8%+8.9%+10.1%+8.1%
Depreciation29.3124.4421.9018.0121.1928.1134.43
Interest16.107.103.511.98(7.37)1.791.97
Profit before tax89.2613814963.0412694.2437.49
Tax23.2036.0138.0416.8024.480.005.15
Net profit64.6810211146.2410194.2432.34
Net profit margin+3.9%+6.5%+7.2%+3.5%+7.0%+8.5%+4.1%
EPS (₹)1.211.852.170.902.122.100.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11011010210295.5689.9689.96
Reserves & surplus1,1331,072787678476311217
Shareholders' funds (net worth)1,2431,182889780598445307
Secured loans44.2453.9628.1925.1618.5717.0513.43
Unsecured loans16041.550.000.000.000.00129
Total debt20595.5128.1925.1618.5717.05142
Total liabilities1,6131,314949836645488474
Assets
Gross block665649477512479516642
Net block403366217171156144135
Capital work in progress8.2228.3424.4517.0114.151.960.00
Investments110205126118118119119
Inventories257286220211258170132
Sundry debtors333294317255222156121
Cash & bank balances59.4046.3350.4855.9045.5566.9838.03
Loans & advances26340325520815110156.35
Total current assets9131,029843731677493348
Total current liabilities278400328267385359188
Net working capital635629515464291133160
Total assets1,6131,314949836645488474
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash24.4315.3021.2615.3840.4712.799.36
Net cash from operating activities20.4729.0877.36(102)(68.87)49.3110.86
Net cash from investing activities(119)(280)(83.60)(36.20)(22.64)(69.09)(12.08)
Net cash from financing activities97.122600.2814466.4147.464.65
Net change in cash(1.43)9.12(5.96)5.88(25.09)27.683.43
Closing cash59.4046.3350.4855.9045.5566.9838.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+1.1%+14.8%-7.6%+30.3%+40.5%-
EBITDA growth-27.0%-5.2%+109.4%-40.2%+14.9%+74.3%-
PBT growth-35.1%-7.6%+136.3%-49.8%+33.2%+151.4%+31.0%
Net income growth-36.3%-8.4%+139.9%-54.3%+7.3%+191.4%-
Revenue CAGR (3Y)+7.9%+2.4%+11.4%+19.1%+26.4%+25.7%+13.1%
EBITDA CAGR (3Y)+13.2%+5.9%+12.9%+6.2%+25.7%+23.1%+2.2%
Profitability & leverage
Net income margin+3.9%+6.5%+7.2%+3.5%+7.0%+8.5%+4.1%
Return on capital employed+7.2%+12.8%+17.1%+8.8%+20.9%+19.6%+8.0%
Return on net worth+5.5%+9.8%+13.3%+6.7%+19.4%+24.4%+9.9%
Debt / equity0.120.060.030.030.030.210.48
Long-term debt / equity0.070.020.000.000.000.000.00
Interest cover19.455.502.513.34-6.832.126.56
Efficiency & per share
Fixed asset turnover2.562.763.112.702.911.921.12
Inventory turnover6.196.147.135.706.777.377.09
Debtors turnover5.365.095.375.617.688.036.51
EPS (₹)1.211.852.170.902.122.100.72
Dividend per share (₹)0.200.200.000.000.000.000.00
Book value per share (₹)22.6821.5617.3915.2611.978.926.83

To see the full year-wise statements and ratios of Morepen Laboratories Limited, buy the company report.

Board of directors of Morepen Laboratories Limited

Morepen Laboratories has 6 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Savita
Also directs: BLS International Services Limited, BLS E-Services Limited, BLS IT Services Private Limited and 1 more
Director22 Jun 20206 Years 4 MonthsCurrent
Sushil Suri
Also directs: Bliss & Blue Ventures LLP, Shivalik Pesticides and Chemicals Pvt Ltd, Morepen Medipath Limited and 5 more
Managing Director20 Oct 201511 Years 0 MonthsCurrent
Sanjay Suri
Also directs: Bliss & Blue Ventures LLP, Shivalik Pesticides and Chemicals Pvt Ltd, Morepen Medipath Limited and 5 more
Whole-Time Director13 Aug 20197 Years 2 MonthsCurrent
Praveen Kumar Dutt
Also directs: Nexiris Global Private Limited, Si Infratel Private Limited
Director13 Aug 20197 Years 2 MonthsCurrent
Ranjit Khattar
Also directs: Xpress Funding Advisors LLP, Dr. Morepen Limited, Eldeco Sohna Projects Limited and 5 more
Director12 Aug 20242 Years 2 MonthsCurrent
Sharad Jain
Also directs: Dr. Morepen Limited
Director27 Aug 20242 Years 1 MonthsCurrent
View all directors

Peer comparison

Morepen Laboratories Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Pfizer Healthcare India Private Limited₹1,981.45 Cr (FY 2025)4.0%Chennai, Tamil Nadu, India
MSN Life Sciences Private Limited₹1,961.87 Cr (FY 2024)54.0%Hyderabad, Telangana, India
Hikal Limited₹1,864.8 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
Aarti Pharmalabs Limited₹1,857.5 Cr (FY 2024)-5.0%Vapi, Gujarat, India
Morepen Laboratories Limitedthis company₹1,805.69 Cr (FY 2026)₹63.79 Cr3.5%-0.3%557Himachal Pradesh, India
MSN Pharmachem Private Limited₹1,716.51 Cr (FY 2024)40.0%Hyderabad, Telangana, India
Indoco Remedies Limited₹1,670.37 Cr (FY 2025)-9.0%Mumbai, Maharashtra, India
Dishman Pharmaceuticals and Chemicals Limited₹1,622.59 Cr (FY 2016)-3.0%Ahmedabad, Gujarat, India
Viyash Scientific Limited₹1,566.06 Cr (FY 2025)13.0%Hyderabad, Telangana, India

To see the full peer comparison of Morepen Laboratories Limited, buy the company report.

Auditor

Morepen Laboratories Limited is audited by S.P BABUTA & ASSOCIATES for the financial year 2025.

Auditor firmFinancial yearFirm registration number
S.P BABUTA & ASSOCIATESFY 2025007657N

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 35.60%, foreign institutional investors hold 1.50%, domestic institutional investors hold 1.30% and retail and other public shareholders hold 61.60%.

Promoters: 35.60%DII (Domestic Institutional): 1.30%FII (Foreign Institutional): 1.50%Retail & Others: 61.60%
Sep 2026
QUARTER
35.60% Promoters
1.30% DII (Domestic Institutional)
1.50% FII (Foreign Institutional)
61.60% Retail & Others
Promoter holding - history
Now 35.60% · Sep 2026High 35.60% · Dec 2025Low 35.60% · Dec 2025
34%34.8%35.5%36.3%37%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 35.60%Mar 2026: 35.60%Jun 2026: 35.60%Sep 2026: 35.60%35.60%35.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters35.60%35.60%35.60%35.60%
Public64.40%64.40%64.40%64.40%

Charges & borrowings

Open charges
₹61.36 Cr
Satisfied charges
₹2,644.6 Cr
Breakdown by lending institutions
Others₹61.36 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
31 Jan 2026101239522Others₹31 LakhOpen
28 Dec 2025101220140Others₹1.22 CrOpen
23 May 2025101108793Others₹50 CrOpen
22 Apr 2025101093377Others₹56.5 LakhOpen
29 Mar 2025101077422Others₹28.4 LakhOpen

To see the full charge records of Morepen Laboratories Limited, buy the company report.

Total charge records: 120 View all charges

Deals & funding

Morepen Laboratories Limited has 66 deals on record (62 market trades, 3 funding rounds, 1 qip), with disclosed funding of ₹907.84 Cr; the latest was in August 2026.

Total deals
66
Market trades
62
Funding rounds
3
QIP
1
Disclosed funding
₹907.84 Cr

Deals on record (5 of 66)

WhenDealAmountParties
Aug 2026Market trade₹145.91 CrBuyer: Qe Securities LLP , Junomoneta Finsol Private Limited , Microcurves Trading Private Limited
Seller: Qe Securities LLP , Junomoneta Finsol Private Limited , Microcurves Trading Private Limited
Aug 2026Market trade₹126.34 CrBuyer: Microcurves Trading Private Limited , Qe Securities LLP , Junomoneta Finsol Private Limited
Seller: Microcurves Trading Private Limited , Qe Securities LLP , Junomoneta Finsol Private Limited
Jun 2026Market trade₹16.7 CrBuyer: Hrti Private Limited
Seller: Hrti Private Limited
Feb 2026Market trade₹48.56 CrBuyer: NK Securities Research Private Limited , Junomoneta Finsol Private Limited , Qe Securities LLP
Seller: NK Securities Research Private Limited , Qe Securities LLP , Junomoneta Finsol Private Limited
Feb 2026Market trade₹44.66 CrBuyer: NK Securities Research Private Limited , Qe Securities LLP
Seller: NK Securities Research Private Limited , Qe Securities LLP

To see the full deal history of Morepen Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Morepen Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Morepen Laboratories has 6 subsidiary companies. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.

6
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Morepen RX LimitedU21001HP2023PLC009940
Dr. Morepen LimitedU24232DL2001PLC111636
Total Care LimitedU24246DL2000PLC105296
Morepen Medipath LimitedU32509HP2025PLC011337
Morepen Devices LimitedU33112HP2021PLC008798
Quick Med Private LimitedU46497HR2025PTC129787

To see the full group structure of Morepen Laboratories Limited, buy the company report.

Employees & EPFO

Morepen Laboratories Limited has a workforce of 557 employees on its EPFO records as of Sep 23, 2025, across 1 active EPFO establishment.

Employee count
557
Active EPFO establishments
1
Employee growth
9.65%

GST

Morepen Laboratories has 23 GST registrations: 13 active and 10 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
23
Active
13
Cancelled / inactive
10
GSTINStateStatusRegistered on
02AABCM1083B1ZAHimachal PradeshActive01 Jul 2017
03AABCM1083B1Z8PunjabActive01 Jul 2017
05AABCM1083B1Z4UttarakhandActive01 Jul 2017
06AABCM1083B1Z2HaryanaActive01 Jul 2017

To see the full GST registrations and return filing status of Morepen Laboratories Limited, buy the company report.

Recent activity

Morepen Laboratories Limited has 22 board changes on record since 1992: 15 appointments and 7 cessations. The latest: Bhupender Raj Wadhwa ceased to be Director on 18 Sep 2024.

Filing
Morepen Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Himachal Pradesh.
Charges
A charge registered on 27 Dec 2024 via Charge ID 101029026 with Others was fully satisfied on 20 Mar 2026.
Charges
A charge with Others amounted to Rs. 0.31 Cr with Charge ID 101239522 was registered on 31 Jan 2026.
Charges
A charge registered on 09 Nov 2022 via Charge ID 100645478 with Others was fully satisfied on 09 Jan 2026.
Charges
A charge registered on 25 Oct 2022 via Charge ID 100654072 with Others was fully satisfied on 09 Jan 2026.
Charges
A charge with Others amounted to Rs. 1.22 Cr with Charge ID 101220140 was registered on 28 Dec 2025.
AGM
Morepen Laboratories Limited last Annual general meeting of members was held on 06 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101108793 was registered on 23 May 2025.
Charges
A charge registered on 26 Apr 2022 via Charge ID 100572633 with Others was fully satisfied on 21 May 2025.
Charges
A charge with Others amounted to Rs. 0.57 Cr with Charge ID 101093377 was registered on 22 Apr 2025.
Charges
A charge with Others amounted to Rs. 0.28 Cr with Charge ID 101077422 was registered on 29 Mar 2025.
Charges
A charge with Others amounted to Rs. 0.10 Cr with Charge ID 101073876 was registered on 11 Mar 2025.

245 earlier events are in the company report.

News

Morepen Labs: Co.submits First U.S. Anda For Sitagliptin, Strengthens Integrated Cdmo Capabilities. First U.s. Anda Submitted For Sitagliptin Tablets Usp In Three Strengths
28 Sep 2026 · Exchange Update

Frequently asked questions

Morepen Laboratories is an active public limited company based in Himachal Pradesh, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 01 December 1984 (42+ years old) and is registered under CIN L24231HP1984PLC006028. Listed on BSE: 500288 and NSE: MOREPENLAB.

Morepen Laboratories reported revenue of ₹1,805.69 Cr for FY 2025-26 (down 0.3% YoY) based on consolidated financials.

Morepen Laboratories has 6 current directors:

The latest financial statements of Morepen Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 06 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Morepen Laboratories is 02AABCM1083B1ZA, registered in Himachal Pradesh. The company has 23 GST registrations in all, of which 13 are active and 10 are cancelled or inactive. Other active GSTINs include 03AABCM1083B1Z8 (Punjab), 05AABCM1083B1Z4 (Uttarakhand), 06AABCM1083B1Z2 (Haryana).

The CIN (Corporate Identification Number) of Morepen Laboratories is L24231HP1984PLC006028. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Morepen Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 500288) and NSE (symbol: MOREPENLAB).

Morepen Laboratories has 637 court cases on record: 403 filed by the company and 234 filed against it. 55 are pending. Most are in the district courts.

Morepen Laboratories was incorporated on 01 December 1984, making it 42+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.

Morepen Laboratories has 66 deals on record (62 market trades, 3 funding rounds, 1 qip), with disclosed funding of ₹907.84 Cr; the latest was in August 2026.

The peers of Morepen Laboratories by revenue are Pfizer Healthcare India Private Limited, MSN Life Sciences Private Limited, Hikal Limited, Aarti Pharmalabs Limited, MSN Pharmachem Private Limited and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).